drugset / Trial / NCT06763666
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
Phase 4
Not yet recruiting
172 enrolled
Nanfang Hospital, Southern Medical University
Affiliated Hospital of Guangdong Medical University · collabCentral People's Hospital of Zhanjiang · collabDongguan People's Hospital · collabFirst Affiliated Hospital of Guangxi Medical University · collabFirst People's Hospital of Foshan · collabForesea Life Insurance Guangzhou General Hospital · collabGuangdong Second Provincial General Hospital · collabGuangzhou First People's Hospital · collabGuangzhou General Hospital of Guangzhou Military Command · collabGuangzhou No.12 People's Hospital · collabGuangzhou Panyu Central Hospital · collabGuilin Medical University, China · collabHainan General Hospital · collabHuizhou Municipal Central Hospital · collabJiangmen Central Hospital · collabLiuZhou People's Hospital · collabMaoming People's Hospital · collabPeking University Shenzhen Hospital · collabSecond Affiliated Hospital of Guangzhou Medical University · collabShantou Central Hospital · collabShenzhen Hospital of Southern Medical University · collabShenzhen Second People's Hospital · collabSouthern Medical University, China · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabTungwah Hospital of Sun Yat-Sen University · collabYuebei People's Hospital · collabZhongshan People's Hospital, Guangdong, China · collabZhuHai Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, prospective, randomized controlled clinical study comparing the efficacy and safety of CLAG+VEN and CLAG regimens in relapsed/refractory(r/r) AML.
Timeline
- Start
- 2025-02
- Primary completion
- 2025-06
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
| Background | Cladribine | Small molecule | 5 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 1 g | Intravenous |
| Background | G-CSF | Unknown | 5 ug/kg | Subcutaneous |